Step Pharma is developing a novel class of oral nucleotide synthesis inhibitors specifically targeting cytidine triphosphate synthase 1 (CTPS1) to induce selective modulation of T and B lymphocyte populations. Step Pharma has identified and optimised small molecule, orally available, potent and selective inhibitors of CTPS1. The most advanced candidate STP938, will enter clinical development targeting hematological malignancies.
Forum 2, 218 avenue Marie Curie, Archamps, 74160, France
Targeting innovation : Lymphoma, Myeloma, Leukemia